Content deleted Content added
No edit summary |
|||
| Line 45: | Line 45: | ||
* [[5F-CUMYL-PINACA]] |
* [[5F-CUMYL-PINACA]] |
||
* [[5F-SDB-006]] |
* [[5F-SDB-006]] |
||
* [[CUMYL-PINACA]] |
|||
* [[CUMYL-THPINACA]] |
* [[CUMYL-THPINACA]] |
||
* [[SDB-006]] |
* [[SDB-006]] |
||
Revision as of 10:24, 11 July 2015
 | |
| Identifiers | |
|---|---|
| |
| CAS Number | |
| Chemical and physical data | |
| Formula | C23H28N2O |
| Molar mass | 348.49 g/mol g·mol−1 |
| 3D model (JSmol) | |
| |
| |
CUMYL-PICA (SGT-56) is an indole-3-carboxamide based synthetic cannabinoid. It is the α,α-dimethylbenzyl analogue of SDB-006.[1] It was briefly sold in New Zealand during 2013 as an ingredient of at the time legal synthetic cannabis products, but the product containing CUMYL-BICA and CUMYL-PICA was denied an interim licensing approval under the Psychoactive Substances regulatory scheme, due to reports of adverse events in consumers.[2] CUMYL-PICA acts as a potent agonist for the cannabinoid receptors, with approximately 20x selectivity for CB1, having an EC50 of 0.66nM for human CB1 receptors and 13nM for human CB2 receptors.[3]
See also
References
- ^ "CUMYL-PICA". Cayman Chemical. Retrieved 8 July 2015.
- ^ The Risk Assessment Score Table. New Zealand Ministry of Health, 27 September 2013
- ^ Bowden; et al. (11 April 2013). "Patent WO 2014167530 - Cannabinoid compounds". New Zealand Patent application 623626. Retrieved 11 July 2015.
{{cite web}}: Explicit use of et al. in:|author=(help)